Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer

PURPOSE: Erlotinib is an orally administered tyrosine kinase inhibitor used for treatment of non-small cell lung cancer. Understanding actual use of medication is essential for optimizing treatment conditions. METHODS: In this multicentre prospective observational study, patients starting erlotinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Timmers, Lonneke, Boons, Christel C. L. M., Moes-ten Hove, J., Smit, Egbert F., van de Ven, Peter M., Aerts, Joachim G., Swart, Eleonora L., Boven, Epie, Hugtenburg, Jacqueline G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469769/
https://www.ncbi.nlm.nih.gov/pubmed/25743274
http://dx.doi.org/10.1007/s00432-015-1935-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469769/
https://www.ncbi.nlm.nih.gov/pubmed/25743274
http://dx.doi.org/10.1007/s00432-015-1935-0

Ejemplares similares